



**World Health
Organization**

INN Working Document 14.349 rev. 2
ENGLISH ONLY
08/01/2015

***Pre-stems*:
Suffixes used in the selection of INN
November 2014***

Programme on International Nonproprietary Names (INN)

Technologies Standards and Norms (TSN)

Regulation of Medicines and other health technologies (RHT)

***World Health Organization,
Geneva***

© World Health Organization (2015) -This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means - electronic, mechanical or other - without the prior written permission of WHO. The views expressed in documents by named authors are solely the responsibility of those authors.

*The prestems given have been flagged because they may be selected as official stems ("The use of stems in the selection of International Nonproprietary Names for Pharmaceutical Substances", 2013, WHO/EMP /RHT/TSN/2013.1). At present, they are made available for information and potential guidance to the applicants.

*stem**-suffix**-infix-***In bold:** new pre-stems selected during the last Consultation.**In bold, underlined:** newly selected stems.*definition*

<i>-algron</i>	α_1 -adrenoreceptor agonists
<i>-ampator</i>	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators
<i>-apt-</i>	aptamers, classical and mirror ones
<u>-asvir</u>	see <i>vir</i>
<i>-axomab</i>	see <i>mab</i>
<i>-berel</i>	estrogen receptor beta agonists
<i>-brutinib</i>	see <i>tinib</i>
<i>-caftor</i>	cystic fibrosis transmembrane regulator (CFTR) protein modulators
<i>-calcet/-calcet-</i>	calcium-sensing receptors (CaSR) agonists
<i>-camra</i>	intracellular adhesion molecule 1 (ICAM-1) derivatives
<i>-casan</i>	caspase converting enzyme inhibitors
<i>-caserin</i>	serotonin receptor agonists (mostly 5-HT ₂)
<i>-catib</i>	cathepsin inhibitors
<i>-citinib</i>	see <i>-tinib</i>
<i>-ciclosporin</i>	ciclosporin derivatives
<i>-codar</i>	see <i>dar</i>
<i>-corat</i>	glucocorticoid receptor agonists
<i>-cridar</i>	see <i>dar</i>

<i>dar</i>	<i>drugs used in multidrug resistance</i>
-cridar	acridinecarboxamide derivatives
-codar	pipecolate derivatives
-spodar	ciclosporin D derivatives
-degib	SMO receptor antagonists
-depsin	depsipeptide derivatives
-dil	<i>vasodilators</i>
-sudil	Rho protein kinase inhibitors
-domide	antineoplastics, thalidomide derivatives
-dustat	see <i>stat</i>
-ectedin	ecteinascidin derivatives
-espib	heat shock protein (HSP) 90 inhibitors (other than -mycin), antineoplastics
-estrant	estrogen antagonists
-fadine	monoamine transport inhibitors
-farnib	farnesyl transferase inhibitors
<u>-fenacin</u>	<u>muscarinic receptor antagonists</u>
-fibatide	see <i>tide</i>
-fulven	antineoplastic, acylfulvene derivatives
-gacestat	see - <i>stat</i>
-ganan	antimicrobial, bactericidal permeability increasing polypeptides
-gepant	calcitonin gene-related peptide receptor antagonists
-gapil	neuronal apoptosis inhibitors, GAPDH
-imepodib	inosine monophosphate dehydrogenase inhibitors
-imod	immunomodulators, both stimulant/suppressive and stimulants
-tolimod	toll-like receptors (TLR) agonists

-isant	histamine H ₃ receptor antagonists
-ixibat	ileal bile acid transporter (IBAT) reabsorption inhibitors
-kalner	openers of calcium-activated (maxi-K) K ⁺ -channels
-laner	antagonists of GABA (gamma-aminobutyric acid)
-leptin(e)	leptin derivatives
<i>mab</i>	<i>monoclonal antibodies</i>
under species	
-axo-	rat-murine hybrid antibodies
under target	
-gr(o)-	skeletal muscle mass related growth factors and receptors
-metinib	see <i>tinib</i>
-moren	non-peptidic growth hormone secretagogues
-nepag	prostaglandins receptors agonists, non-prostanoids
-nesib	kinesin inhibitors
-neurin	neurotrophins
<i>nil</i>	<i>benzodiazepine receptor antagonists/agonists</i>
-punil	mitochondrial benzodiazepine receptor (MBR)- selective agonists also partial or inverse (purine derivatives)
-opran	μ-opioid receptors antagonists
-orexant	orexin receptor antagonists
-osuran	urotensin receptor antagonists
-otilate	hepatoprotectants, diisopropyl-1,3-dithiol-malonate derivatives
-parantag	antagonists of heparin and/or low-molecular weight heparins (LMWH)
-paxar	protease activated receptor type 1 (PAR1) antagonists
-plasinin	inhibitors of plasminogen activator inhibitors-type 1 (PAI-1)

-prazan	proton pump inhibitors, not dependent on acid activation
-prinin	nootropic agents, purine derivatives
-punil	see <i>nil</i>
<u>-ritide</u>	see <i>-tide</i>
-siban	oxytocin antagonists
-siran-	small interfering RNA
-spodar	see <i>dar</i>
-stat/-stat	<i>enzymes inhibitors</i>
-dustat	hypoxia inducible factor (HIF) prolyl hydroxylase inhibitors
-gacestat	gamma-secretase inhibitors
-stinel	NMDA receptor antagonist/agonists, glycine recognition site
-sudil	see <i>dil</i>
-sulind	antineoplastics, sulindac metabolites
-tegravir	see <i>vir</i>
-texafin	texaphyrin derivatives
-tide	<i>peptides and glycopeptides</i>
-fibatide	platelet aggregation inhibitor (GPIIb/IIIa receptor antagonist)
<u>-ritide</u>	<u>natriuretic peptides</u>
-tinib	<i>tyrosine kinase inhibitors</i>
-tinib	acromegaly, chronic myeloid leukemia, tyrosine kinase (Bcr-abl, tyrosine

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27598

